viDA's lead candidate, VTI-1002, is a proprietary small-molecule inhibitor of extracellular Granzyme B. The company is pursuing preclinical development programs in dermatology and ophthalmology, supported by research into the role of extracellular GzmB in tissue damage and repair.
Alistair Duncan co-founded, serves as President and CEO of viDA Therapeutics Inc., and previously led Chromos Molecular Systems Inc. and Agrisoma Biosciences Inc.
viDA Therapeutics develops small-molecule inhibitors targeting Granzyme B for applications in dermatology and ophthalmology, with VTI-1002 as its lead candidate.
viDA Therapeutics develops small-molecule inhibitors targeting Granzyme B for applications in dermatology and ophthalmology, with VTI-1002 as its lead candidate.
Dr. Ron Nardi joins viDA Therapeutics as a member of its Science Advisory Board. The company develops therapeutic solutions in the biopharmaceutical sector. This appointment expands viDA’s expert advisory network.
viDA Therapeutics appoints Dr. Robert P. Ryan to its Board of Directors. Ryan brings expertise in orphan products to the biotech company. The appointment aims to strengthen viDA’s leadership in rare disease therapies.
viDA Therapeutics presents at two biotech investor conferences. The company is selected as a **Next Wave presenter** at BioCentury’s *Future Leaders in the Biotech Industry* conference in New York on **March 28, 2014**. viDA also participates in Life Science Nation’s *Redefining Early Stage Investments* event. The private biotech firm targets early-stage investment opportunities in its presentations.
viDA Therapeutics demonstrates that Granzyme B—its drug program’s primary target—impairs wound healing by degrading the extracellular matrix, delaying closure in apolipoprotein E knockout mice. The findings appear in *Cell Death and Differentiation*, part of the *Nature* portfolio. The company’s research focuses on developing therapies targeting Granzyme B’s effects on tissue repair.
viDA Therapeutics secures **$1.8 million in equity financing** to advance novel drugs targeting the granzyme family of serine proteases for chronic inflammatory and age-related diseases. The round is led by **BDC Venture Capital**, with additional backing from angel investors. The company focuses on first-in-class treatments in its biotechnology pipeline.
Vancouver-based **viDA Therapeutics** develops therapies targeting biological aging mechanisms. The company’s board includes **QLT’s founder**, a biotech veteran. viDA focuses on extending healthspan by intervening in cellular aging pathways, leveraging expertise from its advisory network.
viDA Therapeutics secures an additional **$750,000** in equity financing from BDC Venture Capital, completing a key preclinical milestone for its lead molecule—a granzyme B inhibitor—targeted as a treatment for an unspecified condition. The funding brings the total seed round to approximately **$3.65 million**, enabling continued development of the therapeutic candidate. The milestone achievement validates progress in preclinical stages, supporting viDA’s pipeline advancement.